ARIAD presents new Preclinical data on Ponatinib in solid tumors, demonstrated inhibition of all FGF receptor kinases

Current article ratings:
Patients / public:3 (1 votes)healthcare Prof:
ARIAD pharmaceuticals, Inc. (NASDAQ: ARIA) today announced the results of pre-clinical studies into Ponatinib, investigational Pan BCR-ABL inhibitor, result of strong inhibition of all four members of the fibroblast growth factor receptor (FGFR) family of tyrosine, which unusually are expressed in several types of cancer. ARIAD scientists present the data today morning at the American Association for cancer research (AACR) annual meeting in Orlando, Florida.

Recent research has shown that FGF are activated receptors 1 and 4 by several mechanisms in certain solid tumors and represent promising targets for antitumor therapy. The new data on Ponatinib shows strong activity against a wide range of tumor cells by all four FGFRs, in-vitro and in vivo enabled. In a panel of 14 cell lines, which several types of cancer including endometrial, bladder, stomach, breast, lung and colorectal cancer, Ponatinib potently and selectively FGFR-mediated signaling and cell inhibited growth. Four other tyrosine kinase inhibitors with effect suspending FGFR, which are in clinical development were much less active, and no you blocked all four FGF receptors.

In mouse models of FGFR controlled tumors daily oral doses of Ponatinib reduced tumour growth and inhibited signal 3 FGFR controlled models examined in all. Ponatinib tumor growth by 80 percent in mouse models of bubble and endometrial cancers reducing and induced tumor regression in a model of stomach cancer. Power was similar to that previously observed in BCR-ABL-controlled models of chronic myeloid leukemia (CML). Importantly, shows the phase 1 study of Ponatinib in CML, that plasma levels all four FGFRs at well tolerated doses in patients can be maintained which Ponatinib to inhibit.

"This data, for the first time show that in addition to his profile as a pan-inhibitor of BCR-ABL, Ponatinib is also an investigational Pan-FGFR inhibitor", explains Timothy p. Clackson, PhD., President of the research and development and Chief scientific officer of ARIAD. "The data also show that Ponatinib effectively inhibits this the activity of all four FGFRs on clinically available drug levels and offer strong justification for ponatinib's evaluation in patients with cancer FGFR-controlled."

Source:
ARIAD pharmaceuticals, Inc.